Endothelial p130cas confers resistance to anti-angiogenesis therapy

Mostrar otras versiones (2)

Anti-angiogenic therapies, such as anti-VEGF antibodies (AVAs), have shown promise in clinical settings. However, adaptive resistance to such therapies occurs frequently. We use orthotopic ovarian cancer models with AVA-adaptive resistance to investigate the underlying mechanisms. Genomic profiling...

Descripción completa

Detalles Bibliográficos
Autores principales: Wen, Yunfei, Chelariu-Raicu, Anca, Umamaheswaran, Sujanitha, Nick, Alpa M., Stur, Elaine, Hanjra, Pahul, Jiang, Dahai, Jennings, Nicholas B., Chen, Xiuhui, Corvigno, Sara, Glassman, Deanna, Lopez-Berestein, Gabriel, Liu, Jinsong, Hung, Mien-Chie, Sood, Anil K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860355/
https://www.ncbi.nlm.nih.gov/pubmed/35081345
http://dx.doi.org/10.1016/j.celrep.2022.110301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860355/
https://www.ncbi.nlm.nih.gov/pubmed/35081345
http://dx.doi.org/10.1016/j.celrep.2022.110301

Ejemplares similares